Fulcrum Therapeutics (FULC) News Today → Could this Tiny Biotech End Disease Forever? (From Behind the Markets) (Ad) Free FULC Stock Alerts $7.65 +0.11 (+1.46%) (As of 03:40 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineFulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurologyfinance.yahoo.com - May 8 at 10:23 AMFulcrum Therapeutics (FULC) Set to Announce Earnings on Mondaymarketbeat.com - May 7 at 1:02 PMFulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ETglobenewswire.com - May 6 at 8:00 AMFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from Analystsamericanbankingnews.com - May 4 at 5:38 AMFulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Updatemarketbeat.com - May 1 at 7:20 PMEpsilogen Appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as Part of Broader Company Expansionfinance.yahoo.com - May 1 at 2:37 AM256,888 Shares in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Bought by abrdn plcmarketbeat.com - April 30 at 4:46 AMShort Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Drops By 5.4%marketbeat.com - April 16 at 8:53 AMBiotech on a Budget: 7 Stocks Under $10 With Huge Potentialinvestorplace.com - April 15 at 12:54 PMFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Moderate Buy" from Brokeragesmarketbeat.com - April 9 at 4:10 AMFulcrum Therapeutics (NASDAQ:FULC) Shares Down 4.6% marketbeat.com - April 3 at 4:28 PMFulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposiumfinance.yahoo.com - March 28 at 5:51 PMFulcrum Therapeutics (NASDAQ:FULC) Shares Down 6.2% marketbeat.com - March 25 at 4:23 PMFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - March 22 at 4:30 PMFulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down to $10.10marketbeat.com - March 20 at 12:45 PMFULC Apr 2024 9.000 putfinance.yahoo.com - March 19 at 11:46 PMAnalysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)markets.businessinsider.com - March 19 at 8:45 AMFulcrum Therapeutics, Inc.: Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officerfinanznachrichten.de - March 18 at 4:00 PMFulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.6%marketbeat.com - March 18 at 11:55 AMFulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical Officermsn.com - March 18 at 10:59 AMFulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officerglobenewswire.com - March 18 at 7:00 AMHudson Bay Capital Management LP Buys New Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)marketbeat.com - March 17 at 5:12 AMFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of "Moderate Buy" by Analystsmarketbeat.com - March 15 at 6:41 AMFulcrum Deepens Collaboration with Esri, Recognized as Bronze Partnertmcnet.com - March 13 at 7:22 PMFulcrum Therapeutics (NASDAQ:FULC) Shares Gap Up to $10.91marketbeat.com - March 13 at 12:33 PMFulcrum Therapeutics, Inc. (NASDAQ:FULC) VP Sells $57,240.48 in Stockinsidertrades.com - March 11 at 7:38 AMAdage Capital Partners GP L.L.C. Boosts Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)marketbeat.com - March 9 at 6:36 AMFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - March 8 at 4:30 PMFulcrum hits 52-week high as CEO buys sharesmsn.com - March 8 at 1:53 PMFULC Jun 2024 15.000 callfinance.yahoo.com - March 7 at 3:21 PMCEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stockfinance.yahoo.com - March 7 at 10:20 AMFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by RTW Investments LPmarketbeat.com - March 6 at 11:00 AMFulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conferencefinance.yahoo.com - March 5 at 10:43 AMFulcrum Therapeutics (NASDAQ:FULC) Hits New 12-Month High at $11.42marketbeat.com - March 4 at 10:51 AMFmr LLC Grows Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)marketbeat.com - March 4 at 5:19 AMQ1 2024 EPS Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Reduced by Leerink Partnrsmarketbeat.com - March 2 at 2:28 AMQ2 2024 EPS Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Cut by Analystmarketbeat.com - March 1 at 8:01 AMStrong Buy Rating for Fulcrum Therapeutics Amidst Promising Clinical Progress and Financial Stabilitymarkets.businessinsider.com - March 1 at 7:35 AMFulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call Transcriptseekingalpha.com - February 29 at 4:30 PMFulcrum Therapeutics, Inc. (NASDAQ:FULC) to Post FY2027 Earnings of $0.13 Per Share, HC Wainwright Forecastsmarketbeat.com - February 29 at 9:45 AMDeep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)markets.businessinsider.com - February 28 at 6:16 PMFulcrum Therapeutics Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - February 28 at 6:16 PMHC Wainwright Increases Fulcrum Therapeutics (NASDAQ:FULC) Price Target to $17.00marketbeat.com - February 28 at 2:45 PMFulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 28 at 1:15 PMFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023globenewswire.com - February 27 at 7:00 AMEarnings Preview: Fulcrum Therapeuticsbenzinga.com - February 26 at 5:45 PMFulcrum Therapeutics is about to announce its earnings — here's what to expectmarkets.businessinsider.com - February 26 at 5:45 PMFulcrum Therapeutics (NASDAQ:FULC) Reaches New 1-Year High at $9.97marketbeat.com - February 26 at 10:51 AMDekaBank Deutsche Girozentrale Makes New $268,000 Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)marketbeat.com - February 26 at 5:04 AMFulcrum Therapeutics Stock (NASDAQ:FULC), Short Interest Reportbenzinga.com - February 22 at 6:42 PM Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Could this Tiny Biotech End Disease Forever? (Ad)Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health. Access my full "Cut & Paste" profit analysis now. FULC Media Mentions By Week FULC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FULC News Sentiment▼0.240.37▲Average Medical News Sentiment FULC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FULC Articles This Week▼52▲FULC Articles Average Week Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TRDA News Today TBPH News Today SLRN News Today RVNC News Today PEPG News Today ESPR News Today NGNE News Today ANL News Today LXRX News Today KRRO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FULC) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
